Related Experiment Videos
Clinical trials in isolated systolic hypertension in the elderly
Mario R García-Palmieri1, José M Torrado
1School of Medicine, University of Puerto Rico.
Insights
Pharmacologic treatment of isolated systolic hypertension in the elderly significantly reduces mortality. Evidence-based medicine supports this approach, showing decreased cardiovascular events, stroke, and myocardial infarction in treated patients.
Area of Science:
- Gerontology
- Cardiovascular Medicine
- Pharmacology
Background:
- Isolated systolic hypertension in the elderly is a significant risk factor for severe cardiovascular diseases.
- Conditions linked include coronary artery disease, myocardial infarction, heart failure, stroke, and cardiovascular mortality.
- The justification for pharmacologic management of this condition in the elderly has been a recent focus of research.
Purpose of the Study:
- To review clinical trial results on the pharmacologic management of isolated systolic hypertension in elderly populations.
- To evaluate the efficacy and justification of treating isolated systolic hypertension in older adults based on current evidence.
Main Methods:
- Systematic review of major clinical trials involving thousands of elderly patients with isolated systolic hypertension.
- Presentation and analysis of aggregated results from these trials.
Main Results:
- Pharmacologic treatment demonstrated a 17% reduction in total mortality.
- A 25% reduction in cardiovascular mortality was observed.
- Significant reductions were noted in stroke (37%) and myocardial infarction (25%) among treated patients.
Conclusions:
- Pharmacologic management of isolated systolic hypertension in the elderly is justified by substantial reductions in mortality and major cardiovascular events.
- Evidence-based medicine supports the use of antihypertensive medications in this demographic.
- Treatment leads to improved cardiovascular outcomes and reduced incidence of stroke and myocardial infarction.
Abstract:
The presence of isolated systolic hypertension in elderly subjects predisposes to the development of coronary artery disease, myocardial infarction, heart failure, cardiovascular events, stroke and cardiovascular mortality. Whether pharmacologic management of isolated systolic hypertension in the elderly is justified or not has not received attention until the recent years. In this era of the practice of evidence based medicine it is important to review the results of clinical trials about the management of isolated systolic hypertension involving thousands of elderly patients. The main trials and their results will be presented. These demonstrate a 17% reduction in total mortality, 25% reduction in cardiovascular mortality, 37% reduction in stroke and a 25% reduction in myocardial infarction for those patients under pharmacologic treatment.